Trials / Completed
CompletedNCT00189670
Randomized Phase II Trial of Dose Dense Docetaxel in N+ Breast Cancer
A Phase II Randomized Trial of 6 TEC Every 3 Weeks, Versus 4 EC Followed by 4 Taxotere Every 2 Weeks, Versus 4 Taxotere Followed by 4 EC Every 2 Weeks in Node Positive Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Association Européenne de Recherche en Oncologie · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To screen a dose-dense arm to be used in a future large scale phase III trial. Primary endpoint is safety; secondary endpoints are disease free survival and overall survival. A total of 100 patients were included.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | 6 TEC q 3 weeks | |
| PROCEDURE | 4 EC q 2 weeks followed by 4 TXT q 2 weeks | |
| PROCEDURE | 4 TXT q 2 weeks followed by 4 EC q 2 weeks |
Timeline
- First posted
- 2005-09-19
- Last updated
- 2005-09-19
Source: ClinicalTrials.gov record NCT00189670. Inclusion in this directory is not an endorsement.